Press Releases September 1, 2026 07:00 AM

Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

Tango Therapeutics Announces Participation in 2026 Cantor Global Healthcare Conference Fireside Chat

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
TNGX

Tango Therapeutics, a clinical-stage biotech company focused on precision oncology therapies, will present at the 2026 Cantor Global Healthcare Conference. The company is advancing cancer treatments through synthetic lethality targets and will webcast its management discussion.

Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
TNGX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Tango Therapeutics is a clinical-stage biotechnology company developing precision medicines for cancer treatment.
  • The company leverages synthetic lethality to discover novel drug targets critical to cancer.
  • Tango will participate in a widely followed global healthcare conference with a live and replay webcast accessible to investors.

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (“Tango Therapeutics” or the “Company”) today announced that members of the management team are scheduled to participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 AM EDT.

The live webcast will be available under the "Events & Presentations" tab on the “Investors” page of the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com.

Investors:
Elizabeth Hickin
[email protected]

Media:
1AB
Amanda Lazaro
[email protected]


Risks

  • As a clinical-stage biotech, Tango is subject to risks related to drug development timelines and regulatory approvals.
  • Market and investor response can be sensitive to presentation details and clinical progress updates.
  • The oncology biotechnology sector is competitive and dependent on scientific breakthroughs and patent protections.

More from Press Releases

Heidmar Maritime Holdings Corp. Reports Results for the Second Quarter Ended June 30, 2026 Sep 1, 2026 Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program Sep 1, 2026 NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination for Potential Cardiac Disease and Obesity Therapeutic Applications Sep 1, 2026 Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled Sep 1, 2026 Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) Sep 1, 2026